PRINCE-1: safety and efficacy of atazanavir powder and ritonavir liquid in HIV-1-infected antiretroviral-naive and -experienced infants and children aged ≥ 3 months to < 6 years

Renate Strehlau1, Anamaria Pena Donati2, Pedro Martinez Arce3, Jurgen Lissens4, Rong Yang5, Sophie Biguenet6, Daniela Cambillargiu7, Hélène Hardy8 and Todd Correll9,8

1Corresponding author: Todd Correll, Bristol-Myers Squibb Research and Development, Route 206 & Province Line Rd, Princeton, NJ 08543, USA. Tel: +1 609 252 7214. (todd.correll@bms.com)

Abstract

Introduction: PRINCE-1 is an ongoing prospective, international, multicentre, nonrandomized, two-stage clinical trial assessing safety and efficacy of once-daily atazanavir (ATV) powder boosted with ritonavir (RTV) liquid plus optimized dual nucleoside reverse-transcriptase inhibitor (NRTI) background therapy in antiretroviral (ARV)-naive and -experienced children with HIV-1 infection aged ≥ 3 months to < 6 years.

Methods: Children with HIV-1 infection without prior ATV exposure and with a screening HIV-1 RNA ≥1000 copies/mL were enrolled. The dosing of ATV powder, boosted with 80 mg RTV liquid, was based on three baseline weight bands (5 to <10 kg = 150 mg, 10 to <15 kg = 200 mg and 15 to <25 kg = 250 mg).

Results: Of the 56 treated patients, 46 completed 48 weeks of therapy, 67.9% were from Africa and 60.7% were ART-naive. Median ages at baseline were 6, 35 and 55 months, and proportions with HIV-1 RNA > 100,000 were 85.7, 52.6 and 25% in the three baseline weight bands, respectively. No unexpected safety events occurred and no deaths were reported. Over 48 weeks, upper respiratory tract infections, diarrhea, vomiting and Grade 3 to 4 hyperbilirubinaemia occurred in 35.7, 35.7, 28.6, and 9.4% of patients, respectively; five patients (8.9%) discontinued due to adverse events (AEs); and 11 patients (19.6%) experienced serious adverse events. At Week 48, using a modified intent-to-treat analysis (two patients were excluded because they switched to ATV capsules before Week 48), 61.1 and 74.1% of patients overall had an HIV-1 RNA level <50 copies/mL and <400 copies/mL, respectively. Virologic suppression rates increased across the lowest to highest baseline weight bands (47.6, 68.4 and 71.4% had HIV-1 RNA <50 copies/mL, and 66.7, 73.7 and 85.7% had HIV-RNA <400 copies/mL, respectively) but did not differ meaningfully between ARV-naive and -experienced patients. Overall, the median change from baseline in CD4 cell count was +363 cells/mm³, and the median change from baseline in CD4 percent was +7.5%.

Conclusions: ATV powder boosted with RTV liquid once daily plus optimized dual NRTI background therapy was effective and well tolerated in this ART-naive or -experienced paediatric population aged ≥3 months to <6 years. No unexpected safety findings compared with those from previous ATV paediatric and adult studies were identified.

Keywords: atazanavir powder; ritonavir liquid; HIV-1 infection; antiretroviral therapy; paediatric formulations; infant; child.
therapies for infants and children with HIV-1 infection, there have been few clinical trials in this population to evaluate the efficacy, safety, pharmacokinetics and optimal dosage regimens, particularly in children aged ≤6 years. There have also been relatively few formulations developed for paediatric patients, and treatment options are limited [11].

Only a few ARV drugs are available as palatable formulations (e.g. liquids, minitab sprinkles or powders for reconstitution with water or for mixing with food) suitable for administration to children. PIs currently available as liquid formulations/reconstituted oral suspensions for the treatment of paediatric patients in the United States include fosamprenavir (aged 2 to 18 years) [12], coformulated RTV-boosted LPV (LPV/r) (aged ≥14 days) [13,14], nelfinavir (≥2 years) [15] and RTV-boosted darunavir (DRV/r) (aged 3 to 18 years) [11,16].

Atazanavir (ATV), an azapeptide PI of HIV-1, is indicated for the treatment of HIV-1 infection in combination with other ARV drugs in adults and children and is available in capsule (150 mg, 200 mg, 300 mg) and powder (50 mg) formulations [17]. The open-label, multicentre, Phase I/II PACTG 1020A (AI424-020/NCT00006604) study has shown that combination regimens, including ATV boosted with RTV (ATV/r), are effective and well tolerated in children and adolescents aged ≥6 years [18]. Using data from PACTG 1020A, in which 176 paediatric patients aged 3 months to 21 years received ATV powder or capsules with or without RTV, and data from three adult studies, Hong et al. conducted model-based simulations to identify weight-based ATV doses that were predicted to produce ATV exposures in children similar to those achieved in adults receiving the recommended adult ATV/r dose of 300/100 mg [19].

Results from the Hong et al. modelling study were used to inform the weight-based dosing schedules evaluated in the ATV powder development program studies, PRINCE-1 (AI424-397/NCT01099579) and PRINCE-2 (AI424-451/NCT01335698). Data from the PRINCE studies, together with those from PACTG 1020A, have supported the recent US Food and Drug Administration (FDA) approval of ATV powder for use in paediatric patients ≥3 months of age and weighing ≥10 kg to <25 kg [20]. Here, we present the PRINCE-1 primary safety findings and secondary efficacy results (proportion achieving virologic suppression, reduction in HIV-1 RNA level and increase in CD4 count) over 48 weeks.

Methods
Design
This Phase IIIb, prospective, international, multicentre, non-randomized, two-stage study was conducted in 14 centres across six countries (Brazil, Chile, Mexico, Peru, South Africa and Thailand) and enrolled a cohort of HIV-1-infected paediatric patients aged ≥3 months to <5.5 years. The study was conducted in accordance with good clinical practice (GCP), as defined by the International Conference on Harmonisation (ICH), and in accordance with the ethical principles underlying European Union Directive 2001/20/EC and the US Code of Federal Regulations, Title 21, Part 50 (21CFR50). The study was approved by institutional review boards and independent ethics committees for the participating centers. Informed consent was obtained from all parents/legal guardians and assent from minors who were judged to be at an age of reason. An independent data monitoring committee (DMC) oversaw progress of the study.

Patients
Patients were ARV-naïve or -experienced (without prior exposure to ATV) with screening plasma HIV-1 RNA levels of ≥1000 copies/mL. Treatment-experienced patients were defined as having had previous exposure to ARVs either as prior treatment for HIV-1 infection or as postnatal treatment with ≥1 ARV drug for the prevention of mother-to-child transmission. ARV-naïve patients had to show genotypic sensitivity to ATV and to both components of the local NRTI backbone at screening. ARV-experienced patients had to show genotypic and phenotypic sensitivity to ATV and two NRTIs at screening. NRTIs used were all required to have been approved for paediatric use at the local country level.

Key exclusion criteria were as follows. Children with previous exposure to ATV or ATV/RTV or prior history of two or more failures during PI treatment were excluded in order to assess the investigational formulation in ATV-naïve patients who were unlikely to have PI resistance. Children with documented cardiac conduction abnormality, significant cardiac dysfunction or a history of syncope were excluded on the basis that US treatment guidelines state that LPV/r must be used with caution in patients with pre-existing conduction system defects, because these agents can prolong the PR and QT intervals of the electrocardiogram (ECG) [11]. In addition, ATV is also known to affect the ECG [17] and the study was intended to identify the occurrence of potential drug-related cardiac conduction disorders. Children with coinfection with either hepatitis B virus or C virus were excluded in order to specifically evaluate the effect of the investigational formulation in those with HIV-1 infection only.

Treatments
Backbone therapy consisted of two NRTIs that were approved for paediatric use and administered at doses in accordance with local treatment guidelines. The NRTI regimen was determined by the investigator on the basis of the viral resistance profile and treatment history. The use of tenofovir disoproxil fumarate (TDF) was excluded because of its known pharmacokinetic interaction with ATV (TDF decreases ATV trough concentration by 23% [17]). During Stage 1, eligible ARV-naïve and -experienced HIV-1-infected children between the ages of ≥3 months to <5.5 years with screening plasma HIV-RNA ≥1000 copies/mL received once-daily ATV powder formulation boosted with RTV liquid and two NRTIs (mainly administered twice daily). The dosing schedule for ATV powder and RTV liquid, which was determined by weight bands, is shown in Table 1. ATV powder is available as 50-mg sachets, which were preferably administered with a small amount of food or beverage (e.g. water, milk, infant formula, applesauce or yoghurt). If water was used, the mixture had to be taken with food. RTV liquid was administered immediately before or after ATV powder [21].

Patients who completed 48 weeks on ATV powder transitioned to Stage 2 and continued taking ATV powder. When patients reached six years of age or 25 kg in weight at any
Table 1. Dosing schedule in children aged ≥ 3 months to < 6 years for atazanavir powder and ritonavir liquid by baseline weight bands

| Body weight (kg) | ATV dose (mg) | RTV dose (mg) | Backbone |
|-----------------|--------------|--------------|----------|
| 5 to <10        | 150          | 80           | + approved NRTI backbone |
| 10 to <15       | 200          | 80           | (tenofovir disoproxil fumarate) |
| 15 to <25       | 250          | 80           | was prohibited |

ATV, atazanavir powder; RTV, ritonavir liquid.

time point through 48 weeks, they entered into Stage 2 and transitioned to treatment with ATV and RTV capsules. Data collection for Stage 2 is ongoing and will be reported subsequently.

Outcomes
Assessments were performed at all visits (screening, Day 1 baseline and Weeks 4, 8, 12, 16, 24, 32, 40 and 48).

Primary outcome
The primary outcome was the safety of ATV powder formulation boosted with RTV liquid as part of a CART regimen in paediatric patients dosed through 48 weeks (or a minimum of 24 weeks for patients aged 5.5 years at the time of the study start). Safety endpoints included the following: the frequency of general adverse events (AEs), serious adverse events (SAEs), AEs considered related to study treatment and AEs leading to discontinuation of study treatment; Centers for Disease Control (CDC) Class C AIDS events (the 2008 classification system [22] was used as this was the system in place at the time of data collection and analysis, rather than the recently published 2014 classification [23]); and Grade 3 to 4 laboratory abnormalities, classified according to the Division of AIDS grading system [24], with the highest toxicity grade reported for each laboratory test.

Secondary outcomes
The efficacy of treatment with the proportion of patients with virologic suppression, as defined by HIV-1 RNA <50 copies/mL or <400 copies/mL at Week 48, using the Roche Amplicor HIV-RNA Assay (version 1.5; Roche Diagnostic Systems, Inc., Branchburg, NJ, USA). Efficacy endpoints were summarized by baseline weight band (5 to <10 kg, 10 to <15 kg and 15 to <25 kg) and by prior ARV use (ARV-naïve or ARV-experienced patients).

Virologic suppression rates at Week 48 were analyzed using a modified intent-to-treat (ITT) approach where the numerator was based on the number of patients with on-treatment HIV-1 RNA values <50 (or <400) copies/mL at Week 48 and the denominator was based on patients with available HIV-1 RNA values at Week 48.

Other efficacy assessments included changes from baseline at Week 48 in HIV-1 RNA log_{10} values, CD4 cell count and CD4 percentage.

Viral genotypic and phenotypic resistance profiles were assessed in patients who experienced virologic failure and who met the criteria for resistance testing. The criteria for virologic failure were as follows: (1) a confirmed <1 log_{10} decrease from baseline in HIV-1 RNA levels by Week 16; or (2) a confirmed HIV-1 RNA level of >200 copies/mL after Week 24; or (3) repeated HIV-1 RNA levels of ≥50 copies/mL after Week 48; or (4) a confirmed HIV-1 RNA level of ≥400 copies/mL occurring at any time in a patient who had previously achieved an HIV-1 RNA level of <50 copies/mL. The criteria for resistance testing were as follows: (1) meeting criteria for virologic failure; or (2) discontinuing study treatment for any reason other than withdrawal of consent. HIV-1 isolates were tested for phenotypic resistance using the Phensense™ HIV assay (Monogram Biosciences, Inc., South San Francisco, CA, USA). HIV substitutions were determined using the GeneSeq™ HIV assay (Monogram Biosciences, Inc.). Both assays request/require a viral load >400 copies/mL.

Newly emergent genotypic substitutions were defined as on-treatment substitutions that were not detected at baseline.

Newly emergent phenotypic resistance was defined as a baseline fold change less than the cut-off for reduced susceptibility and an on-treatment fold change greater than the cut-off for reduced susceptibility.

The acceptability and palatability of ATV powder and RTV liquid were assessed using a caregiver questionnaire administered at each study visit, in which caregivers were asked if their child had any trouble completing the dose of ATV powder or RTV liquid (acceptability). Reasons for having trouble completing the dose included dislike of taking medicines generally, specific dislike of the taste of the study medications (palatability) and regurgitation of the dose.

The pharmacokinetic profile of ATV powder formulation administered with RTV liquid was also evaluated in this study, as well as in the PRINCE-2 study. Given that the ongoing PRINCE-2 study evaluates a higher dose of ATV (200 mg) in the 5 to <10 kg baseline weight band, an additional baseline weight band of 25 to <35 kg and an age range of 6 to <11 years, none of which were represented in PRINCE-1, pharmacokinetic results from both studies will be presented in a future combined publication.

Statistical analyses
Given that the primary outcome was the safety of the ATV powder formulation boosted with RTV liquid, formal statistical hypothesis testing was not planned and accordingly power calculations were not undertaken. However, a target sample size of 50 treated patients can detect, with 80% probability, a safety event that occurs at a per patient incidence rate of 3.2%.

Descriptive summaries were presented for treated patients in total, categorized by baseline weight band (5 to <10 kg, 10 to <15 kg and 15 to <25 kg) or by prior ARV experience (ARV-naïve, ARV-experienced). No statistical comparisons
between subgroups were conducted, and only summary statistics were presented. Categorical variables were summarized with counts and percentages or with proportions (number with event divided by number evaluable) expressed as percentages. For the percentages of patients with virologic suppression, exact binomial 95% confidence intervals (CI) were calculated. Continuous variables were summarized with univariate statistics. All analyses were conducted using the statistical software SAS® version 9 (SAS Institute, Inc., Cary, NC, USA).

Results

Patients

Of 82 screened patients from 14 sites, 56 (68%) were successfully enrolled and treated (Table 2). Of these 56 treated patients, 46 (82%) completed Stage 1. Nine patients (16%) discontinued before Week 48, with the most common reason for discontinuation of ATV powder being an AE (five patients), particularly in the lowest weight band. One patient discontinued treatment at Week 48 due to poor/non-compliance. One patient withdrew consent and two patients discontinued due to lack of efficacy. At baseline, the majority of patients were ARV-naïve (60.7%). Median ages at baseline were 6, 35 and 55 months; proportions with HIV-1 RNA > 100,000 were 85.7, 52.6 and 25%; and median CD4 counts were 1815, 1002 and 669 cells/mm³ in the three baseline weight bands, respectively (Table 2). Overall, the most frequent NRTI backbone, chosen according to local guidelines and the patient’s viral resistance profile at screening, was abacavir/lamivudine.

Safety

General AEs

No deaths were reported. Eleven patients (19.6%) treated with ATV powder had on-treatment SAEs. Herpes zoster was the only SAE reported in two or more patients (3.6%), occurring in two patients, and was considered unrelated to study therapy by the investigator.

Five patients (8.9%) had AEs leading to discontinuation of study therapy: four in the 5 to <10 kg group (meningitis \( n = 1 \) and pulmonary tuberculosis \( n = 1 \) considered unrelated to study therapy by the investigator; increased transaminases \( n = 1 \) and lymphadenitis \( n = 1 \) considered related events) and 1 in the 10 to <15 kg group (prolonged QT interval that was also considered an SAE). The patient discontinuing ATV due to increased transaminases had a history of nevirapine-induced hepatitis and was receiving concomitant hydroxyzine, an agent known to cause liver dysfunction [25]. In this patient, transaminase measurements returned to normal 30 days after discontinuation of study therapy without the need for specific treatment. In the patient with QT prolongation, a Fridericia’s corrected QT (QTcF) interval of 477 msec was observed, on a protocol-scheduled ECG, on Day 163 compared with a baseline value of 382 msec. The study investigator considered the QT prolongation to be related to study therapy, which was discontinued on Day 170. However, the patient was also receiving concomitant metronidazole and sulfamethoxazole-trimethoprim, both of which have been reported to cause QT prolongation [26,27]. Repeated ECGs after study drug discontinuation showed a normal QT interval without the need for specific treatment.

Through Week 48, the majority of patients on ATV powder (92.9%) had at least one AE, with the most common being upper respiratory tract infection, diarrhoea and vomiting (Table 3). The most common AEs considered related to study therapy by the investigator were hyperbilirubinaemia (seven patients, 12.5%) and vomiting (five patients, 8.9%). Among the seven patients with AEs of hyperbilirubinaemia, two also had AEs of clinical jaundice, but none of these patients discontinued study therapy due to hyperbilirubinaemia.

Other significant AEs

Three patients (5.4%) had cardiac disorders. Two of these events were considered related to the study therapy by the investigator: ECG QT prolongation in one patient in the 10 to <15 kg group (described above in the section on AEs leading to discontinuation) and first-degree atioventricular block in one patient in the 15 to <25 kg group. Eight patients (14.3%) had rash events, none of which were considered related to the study therapy by the investigator. One patient (1.8%) in the 5 to <10 kg group had pulmonary tuberculosis, a CDC Class C AIDS event [22], which was considered unrelated to study therapy by the investigator. Two patients (3.6%) had renal toxicity events, both considered unrelated to study therapy by the investigator (proteinuria in one patient in the 10 to <15 kg group and dysuria in one patient in the 10 to <15 kg group). None of the patients had lipodystrophy-related events.

Laboratory abnormalities

The most common Grade 3 to 4 laboratory abnormality was elevated total serum amylase (26.4%); however, all of these patients had normal fractionated pancreatic amylase levels. Grade 3 to 4 elevations in total bilirubin were present in 5/53 (9.4%) of patients and appeared not to systematically vary by baseline weight band. Grade 3 to 4 elevations in serum transaminases were present in 7/53 (13.2%) of patients, but no instance of drug-induced liver injury was reported. Other Grade 3 to 4 laboratory abnormalities are summarized in Table 3.

Efficacy

Using a modified ITT approach based on the Week 48 ATV powder cohort (patients who did not switch to the ATV capsule at or before Week 48), 61.1% of patients had HIV-1 RNA levels of < 50 copies/mL and 74.1% had HIV-1 RNA levels of < 400 copies/mL. Virologic suppression rates increased progressively across the lowest to highest baseline weight bands (Figure 1). Virologic suppression rates were generally higher across all baseline weight bands in the analysis using observed values; however, similar to the modified ITT analysis, rates in the lowest weight band were lower than those in the two higher weight bands for both HIV-1 RNA < 50 and < 400 copies/mL thresholds (Figure 1).

Virologic suppression rates showed no clear numeric differences between ARV-naïve and -experienced patients (Figure 2).

Virologic suppression rates improved progressively over time for all patients (Figure 3a), regardless of method of
analysis (modified ITT vs. observed values) or threshold HIV-1 RNA level (\(\text{B}50\) copies/mL vs. \(\text{B}400\) copies/mL).

At Week 48, the overall mean change from baseline in HIV-1 RNA levels was \(-2.66\) log\(_{10}\) copies/mL (\(-2.61, -2.93\) and \(-2.40\) log\(_{10}\) copies/mL in the 5 to < 10 kg, 10 to < 15 kg and 15 to < 25 kg groups, respectively).

The acceptability of ATV powder was higher than that for RTV liquid over the first 24 weeks. Drug acceptability tended to improve over time for both treatments (Figure 3b) but remained slightly higher for ATV powder at Week 48 (the majority of patients had no trouble completing their doses; 91.1 and 86.7% for ATV powder and RTV liquid, respectively).

### Table 2. Patient disposition and baseline characteristics

| Body weight at baseline | 5 to < 10 kg (N = 21) | 10 to < 15 kg (N = 19) | 15 to < 25 kg (N = 16) | Total (N = 56) |
|-------------------------|-----------------------|-----------------------|-----------------------|----------------|
| **Patient disposition** |                       |                       |                       |                |
| Treated                 | 21                    | 19                    | 16                    | 56             |
| Completed Stage 1 period (%) | 17 (81)            | 14 (73.7)            | 15 (93.8)            | 46 (82.1)      |
| Discontinued before Week 48 | 4 (19)              | 4 (21.1)             | 1 (6.3)              | 9 (16.1)       |
| Adverse events          | 4 (19)                | 1 (5.3)               | 0                    | 5 (8.9)        |
| Withdrew consent        | 0                     | 0                     | 1 (6.3)              | 1 (1.8)        |
| Lack of efficacy        | 0                     | 2 (10.5)              | 0                    | 2 (3.6)        |
| Poor/noncompliance      | 0                     | 1 (5.3)               | 0                    | 1 (1.8)        |
| Age in months, median (min–max) | 6 (3–15)          | 35 (21–54)           | 55 (34–65)           | 28.5 (3–65)    |
| Female, n (%)           | 10 (47.6)             | 12 (63.2)             | 6 (37.5)             | 28 (50)        |
| Region (%)              |                       |                       |                       |                |
| Africa                  | 17 (81)               | 13 (68.4)             | 8 (50)               | 38 (67.9)      |
| Asia                    | 0                     | 1 (5.3)               | 0                    | 1 (1.8)        |
| North America           | 2 (9.5)               | 3 (15.8)              | 4 (25)               | 9 (16.1)       |
| South America           | 2 (9.5)               | 2 (10.5)              | 4 (25)               | 8 (14.3)       |
| Weight in kg, median (min–max) | 6.9 (5.4–9.3)        | 12.0 (10.7–14.8)     | 16.0 (15.0–21.1)     | 11.6 (5.4–21.1) |
| HIV-1 RNA log\(_{10}\) copies/mL, median (min–max) | 5 (2.8–5)           | 5 (4–5)               | 4.28 (3.1–5)        | 5 (2.8–5)      |
| HIV-1 RNA >100,000 copies/mL, n (%) | 18 (85.7)          | 10 (52.6)             | 4 (25)               | 32 (57.1)      |
| CD4 cells/mm\(^3\), median (min–max) | 1815 (84–3451)     | 1002 (46–2172)       | 669 (106–1019)       | 1004 (46–3451) |
| CD4 percent categories (%) |                       |                       |                       |                |
| <15                     | 2 (9.5)               | 2 (10.5)              | 1 (6.3)              | 5 (8.9)        |
| 15 to <25               | 7 (33.3)              | 6 (31.6)              | 4 (25)               | 17 (30.4)      |
| ≥25                     | 7 (33.3)              | 6 (31.6)              | 6 (37.5)             | 19 (33.9)      |
| Not reported            | 5 (23.8)              | 5 (26.3)              | 5 (31.3)             | 15 (26.8)      |
| ARV-experienced patients | 8 (38.1)              | 7 (36.8)              | 7 (43.8)             | 22 (39.3)      |
| Prior ARVs received     |                       |                       |                       |                |
| Abacavir                | 1/8 (12.5)            | 0                     | 2/7 (28.6)           | 3/22 (13.6)    |
| Didanosine              | 0                     | 1/7 (14.3)            | 0                    | 1/22 (4.5)     |
| Efavirenz               | 0                     | 1/7 (14.3)            | 3/7 (42.9)           | 4/22 (18.2)    |
| Emtricitabine           | 0                     | 0                     | 1/7 (14.3)           | 1/22 (4.5)     |
| Lamivudine              | 1/8 (12.5)            | 4/7 (57.1)            | 6/7 (85.7)           | 11/22 (50.0)   |
| Lopinavir/ritonavir     | 1/8 (12.5)            | 4/7 (57.1)            | 4/7 (57.1)           | 9/22 (40.9)    |
| Nevirapine              | 7/8 (87.5)            | 2/7 (28.6)            | 2/7 (28.6)           | 11/22 (50.0)   |
| Ritonavir               | 0                     | 1/7 (14.3)            | 0                    | 1/22 (4.5)     |
| Stavudine               | 0                     | 3/7 (42.9)            | 4/7 (57.1)           | 7/22 (31.8)    |
| Zidovudine              | 1/8 (12.5)            | 3/7 (42.9)            | 2/7 (28.6)           | 6/22 (27.3)    |
| Backbone NRTIs administered |                       |                       |                       |                |
| Abacavir                | 17 (81.0)             | 16 (84.2)             | 13 (81.3)            | 46 (82.1)      |
| Didanosine              | 0 (0)                 | 2 (10.5)              | 0 (0)                | 2 (3.6)        |
| Lamivudine              | 20 (95.2)             | 12 (63.2)             | 9 (56.3)             | 41 (73.2)      |
| Stavudine               | 0 (0)                 | 1 (5.3)               | 3 (18.8)             | 4 (7.1)        |
| Zidovudine              | 5 (23.8)              | 6 (31.6)              | 10 (62.5)            | 21 (37.5)      |

Strehlau R et al. Journal of the International AIDS Society 2015, 18:19467
http://www.jiasociety.org/index.php/jias/article/view/19467 | http://dx.doi.org/10.7448/IAS.18.1.19467
ATV powder was more palatable than RTV liquid over the first 24 weeks. Drug palatability tended to improve after 16 weeks for both treatments (Figure 3b), but ATV powder remained more palatable than RTV liquid at Week 48 (6.7 and 11.1% of patients disliked the taste of ATV powder and RTV liquid, respectively). Most caregivers mixed ATV powder with water (48.9%) or milk (28.9%). There were no numeric differences between the lowest baseline weight band and the two higher baseline weight bands combined in rates of acceptability at Week 48 for ATV powder (5.9% vs. 7.1%, respectively) or RTV liquid (11.8 and 10.7%, respectively).

Immunologic recovery was observed across all baseline weight bands, with a trend to greater changes from baseline in CD4 percent in the higher versus the lower baseline weight bands (Table 3). Despite baseline CD4 cell count levels being comparable between the ARV-naïve and -experienced groups, changes from baseline in CD4 cell count and CD4 percent were lower in ARV-experienced patients compared with ARV-naïve patients at Week 48 (Table 3).

Resistance data
By Week 48, 14 of 46 (30.4%) patients met the criteria for virologic failure. Of these 14 patients, six (42.9%) were ARV-experienced and eight (57.1%) were ARV-naïve. Nine patients had paired genotypic resistance data (baseline and on-treatment data) and six had paired phenotypic data. None of the patients acquired phenotypic resistance.
to ATV, ATV/RTV or any NRTI or NNRTI. One patient developed phenotypic resistance to saquinavir. None of the patients developed any major PI substitution to ATV or ATV/RTV.

**Discussion**

ATV powder boosted with liquid RTV in combination with optimized NRTI background therapy in infants and children aged three months to six years with HIV-1 infection was generally safe and well tolerated, with a safety profile similar to that reported using ATV capsules in adult studies [28–C130] and in paediatric patients aged ≥ 6 years [18]. No new safety findings were identified that have not been previously reported in the aforementioned studies. Although not considered related to study therapy at the time of documentation, it is possible that the two instances of herpes zoster infection (one commencing on Day 14 and the other on Day 23) may have been caused by immune reconstitution inflammatory syndrome (IRIS), as they occurred within the 2- to 31-week window of onset for IRIS [31]. Therefore, these infections may have been indirectly related to study therapy. Similarly, the case of lymphadenitis, which occurred on Day 115 and was considered related to study therapy, may have been caused by IRIS. However, it should be noted that AEs in this study were extensively documented by study investigators and none were considered to be due to IRIS at the time.

![Figure 1. Percentage of patients achieving virologic suppression by baseline weight bands at Week 48: (a) HIV-1 RNA <50 copies/mL and (b) HIV-1 RNA <400 copies/mL.](image1)

ITT, intent-to-treat. aTwo patients were not included in this analysis because they had switched to ATV capsules before Week 48. Data are proportions expressed as percentages with exact binomial 95% confidence intervals (CI).

![Figure 2. Percentage of patients achieving virologic suppression by prior antiretroviral experience at Week 48: (a) HIV-1 RNA <50 copies/mL and (b) HIV-1 RNA <400 copies/mL.](image2)

ITT, intent-to-treat. aTwo patients were not included in this analysis because they had switched to ATV capsules before Week 48. Data are proportions expressed as percentages with exact binomial 95% confidence intervals (CI).
Virologic suppression rate was lower in the 5 to <10 kg baseline weight band, which most likely resulted from the higher proportion of patients with a baseline plasma HIV-1 RNA level >100,000 seen in this group (85.7% compared with 52.6 and 25.0% in the 10 to <15 kg and 15 to <25 kg groups, respectively). A high plasma HIV-1 RNA level is commonly seen in infancy (the median age of patients in the 5 to <10 kg baseline weight band was six months), which, together with immunological immaturity, makes virologic suppression in infants more difficult to achieve and results in longer times to reach undetectable levels [32,33].

Potential alternative explanations for the lower virologic suppression rate in the 5 to <10 kg baseline weight band, such as the effect of prior ARV exposure, emergent resistance, differences in discontinuation rate or differences in acceptability/palatability were not supported by the available evidence. We found no difference in virologic suppression between ARV-naïve and -experienced patients. None of the patients who underwent resistance testing for virologic failure or discontinuation from the study acquired phenotypic resistance to ATV, ATV/RTV or any NRTI or NNRTI, and no major mutations associated with ATV resistance were reported. Discontinuation rates were not numerically different between the 5 to <10 kg and 10 to <15 kg baseline weight bands and, when analyzed using observed values, virologic suppression rates in the 5 to <10 kg baseline weight band remained numerically lower than those in the other baseline weight bands. Patients in the lowest baseline weight band had neither more trouble completing their doses, nor a greater dislike of the taste of study treatments compared with patients in the higher baseline weight bands. Whether pharmacokinetic differences could explain the lower virological suppression rate in the 5 to <10 kg baseline weight, especially because drug metabolism is known to differ substantially in infancy [34], will be fully explored in a forthcoming publication when these data are available.

Although making comparisons with paediatric clinical studies of other PIs is difficult owing to differences in trial design and endpoint definitions, the results of the current study are consistent with those from studies evaluating LPV/r and other PIs in paediatric populations. In the original study in children aged 6 months to 12 years with HIV-1 infection evaluating LPV/r, either added to stavudine and lamivudine (ARV-naïve) or nevirapine plus one or two NRTIs (ARV-

——

Figure 3. (a) Virologic suppression over time and (b) acceptability and palatability of ATV powder and RTV liquid.

Table 4. Immunologic recovery by baseline weight bands and prior antiretroviral experience at Week 48

| Baseline | Change from baseline at Week 48 |
|----------|---------------------------------|
|          | $N$ | Mean (median) CD4 cell count | n1 | Mean (median) CD4 cell count | n2 | Mean (median) CD4 percent |
| Baseline weight 5 to <10 kg | 16 | 1594 (1815) | 13 | 550 (491) | 14 | 6.1% (6.0%) |
| Baseline weight 10 to <15 kg | 13 | 1107 (1002) | 11 | 225 (274) | 12 | 7.3% (7.5%) |
| Baseline weight 15 to <25 kg | 10 | 661 (669) | 5 | 374 (363) | 6 | 8.8% (9.5%) |
| ARV-naïve | 25 | 1202 (1019) | 20 | 493 (520) | 22 | 8.8% (9.0%) |
| ARV-experienced | 14 | 1175 (970) | 9 | 182 (213) | 10 | 3.2% (2.5%) |
| Total | 39 | 1193 (1004) | 29 | 397 (363) | 32 | 7.0% (7.5%) |

$N$, the number of patients with available baseline CD4 values; n1, the number of patients with available baseline and Week 48 CD4 cell count values; n2, the number of patients with available baseline and Week 48 CD4 percent values; ARV, antiretroviral.
experienced, overall, 79% had HIV-1 RNA levels <400 copies/mL at Week 48 using an ITT analysis. Similarly, in the PENPACT-1 trial, rates of virologic suppression with PIs (mainly LPV/r or nelfinavir) plus two NRTIs at Week 24 were 73% using an ITT analysis [35]. The more recent randomized P1060 trial conducted in resource-limited settings evaluated initial treatment with zidovudine, lamivudine and either nevirapine or LPV/r in children aged 2 to 36 months with HIV-1 infection without prior exposure to nevirapine. In this trial, virologic failure (a confirmed plasma HIV-1 RNA level <1 log_{10} copies/mL below the baseline level at 12 to 24 weeks after treatment initiation or a confirmed plasma HIV-1 RNA level of >400 copies/mL at 24 weeks) or treatment discontinuation occurred in 19.3% of patients randomized to LPV/r [36]. In patients with prior exposure to nevirapine, virologic failure or treatment discontinuation with LPV/r occurred in a slightly higher proportion (21.7%) compared with patients without prior exposure to nevirapine [37]. Recent studies evaluating fosamprenavir liquid boosted with RTV liquid have shown proportions achieving HIV-1 RNA levels <400 copies/mL (snapshot analyses) of 58% in patients aged 4 weeks to <6 months [38], 65% in patients aged 4 weeks to <2 years [39] and 74% in patients aged 2 years to <6 years [39]. Data on the use of DRV/r in children with HIV-1 infection are limited to ARV-experienced patients aged 6 to 17 years, of whom 59% achieved an HIV-1 RNA level <400 copies/mL after 48 weeks of treatment [40].

The acceptability of ATV powder boosted with RTV liquid was high among caregivers of the children in this study, with acceptability over 48 weeks ranging from 71.7 to 91.1% with ATV powder and from 62.3 to 86.7% with RTV liquid. The proportion of children reported by their caregivers as disliking the taste of ATV powder boosted with RTV liquid was low, with up to 12.5% disliking the taste of ATV powder over 48 weeks and up to 27.5% disliking the taste of RTV liquid over 48 weeks. These results compare favourably with the recently evaluated minitab sprinkles formulation of LPV/r, for which 38 to 53% of children <4 years of age were reported by their caregivers to have disliked the taste of the sprinkles [14].

Taken together, these findings on efficacy, safety and acceptability/palatability indicate that a regimen including ATV powder boosted with RTV liquid represents a new treatment option for infants and children aged ≥3 months to <6 years with HIV-1 infection. Indeed, data for this study have contributed to the recent FDA approval of ATV powder formulation for use for use in paediatric patients with HIV-1 infection ≥3 months of age and weighing ≥10 kg to <25 kg [20].

This study has limitations. The study enrolled a relatively small number of patients with HIV-1 infection, was non-randomized, and no statistical comparisons between subgroups were performed (by baseline weight band or ARV treatment experience). Numerically, virologic suppression rates were lower in patients in the lowest baseline weight band compared with the higher weight bands, and immunological recovery was less evident in ARV-experienced patients compared with ARV-naïve patients. However, the study design and small sample size did not allow these observations to be statistically verified. Over 48 weeks, up to 27.5% of patients were reported by their caregivers to have disliked the taste of RTV liquid. This percentage is lower than in a previous study assessing ARV adherence and palatability in children, of whom 50% disliked the taste of RTV liquid [41]. It should be noted that the palatability survey employed in our study was based upon caregiver report and may have underestimated the extent of children’s dislike of the taste of RTV.

In conclusion, no new safety findings were identified that had not been previously reported in other ATV paediatric or adult studies. ATV powder boosted with liquid RTV in combination with optimized NRTI background therapy achieved adequate virologic suppression and immunologic response, was highly acceptable to caregivers, and was generally safe and well tolerated by infants and children aged three months to six years, regardless of prior ARV treatment experience or baseline weight band. No major PI substitutions associated with ATV resistance were reported. As recognized by the recent FDA approval, ATV powder is an available treatment option for use in paediatric patients with HIV-1 infection ≥3 months of age and weighing ≥10 kg to <25 kg.

Authors’ affiliations
1Rahima Moosa Mother & Child Hospital, Johannesburg, South Africa; 2Hospital Sotero Del Rio, Santiago, Chile; 3Hospital Civil Fray Antonio Alcande, Guadalajara, Mexico; 4Bristol-Myers Squibb Research and Development, Braine L’Alleud, Belgium; 5Bristol-Myers Squibb Research and Development, Wallingford, CT, USA; 6AbbVie, North Chicago, IL, USA; 7Bristol-Myers Squibb Research and Development, Buenos Aires, Argentina; 8Bristol-Myers Squibb Research and Development, Princeton, NJ, USA

Competing interests
RS, APD and PMA declare that they have no competing interests. SB was an employee of Bristol-Myers Squibb while the present study was initiated but is currently an employee of AbbVie. JL, RC, HH and TC are employees of Bristol-Myers Squibb.

Authors’ contributions
Study design and implementation: RS, APD, PMA, JL, SB, DC, HH and TC. Data analysis: JL and RC. Manuscript drafting and final approval: RS, APD, PMA, JL, RC, SB, DC, HH and TC. All authors have read and approved the final version.

Acknowledgements and funding
This study was supported by Bristol-Myers Squibb, the manufacturer of atazanavir. The authors thank Caroline Perry and Julian Martins of InScience Communications, Springer Healthcare, who provided medical writing assistance, which was funded by Bristol-Myers Squibb.

References
1. UNICEF. UNICEF data: monitoring the situation of children and women [Internet]. 2013 Dec 11 [cited 2014 Jul 11]. Available from: http://data.unicef.org/hiv-aids/global-trends
2. Gray I, Newell ML, Thorne C, Peckham C, Levy J. Fluctuations in symptoms in human immunodeficiency virus-infected children: the first 10 years of life. Pediatrics. 2001;108(1):116–22.
3. Dunn D. Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis. Lancet. 2003;362(9396):1605–11.
4. Violiari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA, et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med. 2008;359(21):2233–44.
5. Brady MT, Oleske JM, Williams PL, Eigie C, Mofenson LM, Dankner WM, et al. Declines in mortality rates and changes in causes of death in HIV-1-infected children during the HAART era. J Acquir Immune Defic Syndr. 2010;53(1):86–94.
6. United Nations. UNAIDS World AIDS Day report 2012 [Internet]. 2012 [cited 2014 Jun 24]. Available from: http://www.unaids.org/en/media/unaids/ contentassets/documents/epidemiology/2012/gr2012/JC2434_WorldAIDSDay_results_en.pdf

7. World Health Organization. Consolidated guidelines on the use of anti-retroviral drugs for treating and preventing HIV infection: recommendations for a public health approach [Internet]. 2013 Nov [cited 2014 Jun 25]. Available from: http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf?ua=1

8. PENTA Steering Committee. PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection. Med Heli. 2009;20:591–613.

9. Gortmaker SL, Hughes M, Cervia J, Brady M, Johnson GM, Seage GR 3rd, et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med. 2001;345(21):1522–8.

10. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services [Internet]. 2014 May 1 [cited 2014 Jun 24]. Available from: http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf

11. Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. Department of Health and Human Services [Internet]. 2014 Feb 12 [cited 2014 Jun 11]. Available from: http://aidsinfo.nih.gov/contentfiles/ksguidelines/pediatricguidelines.pdf

12. ViiV Healthcare. Prescribing information for fosamprenavir (Telzir®) [Internet]. 2009 Sep [cited 2014 Sep 4]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/206352s000,2221165009lbl.pdf

13. Bristol-Myers Squibb Company. Prescribing information for REYATAZ® [Internet]. 2011 Jun [cited 2014 Sep 4]. Available from: http://www.rxabbvie.com/pdf/kaletratabpi.pdf

14. Musilme V, Villelles O, Kekiniwa A, Kendall L, Keshanyu R, Namuddu R, et al. The pharmacokinetics and acceptability of lopinavir/ritonavir miniabs sprinkles, tablets, and syrups in African HIV-infected children. J Acquir Immune Defic Syndr. 2014;66(2):148–54.

15. ViiV Healthcare Company. Prescribing information for nefavir (VIRACEPT®) [Internet]. 2013 May [cited 2014 Sep 4]. Available from: http://www.viivhealthcare.com/media/32259/us_viracept.pdf

16. Iannsen Pharmaceuticals Inc. PREZISTA® (darunavir) full prescribing information [Internet]. 2014 Apr [cited 2014 Sep 4]. Available from: http://www.prezista.com/sites/default/files/pdf/us_package_insert.pdf#zoom=100

17. Bristol-Myers Squibb Company. Prescribing information for REVLAMAT® [atazanavir] [Internet]. 2014 Jun [cited 2014 Jun 24]. Available from: http://packageinserts.bms.com/pi/us_relyataz.pdf

18. Deeks ED. Atazanavir: in pediatric patients with HIV-1 infection. Paediatr Drugs. 2012;14(2):131–41.

19. Hong Y, Kowalski KG, Zhang L, Zhi L, Horga M, Berz T, et al. Model-based approach for optimization of atazanavir dose recommendations for HIV-infected pediatric patients. Antimicrob Agents Chemother. 2011;55(12):5746.

20. US Food and Drug Administration. New pediatric dosage form and label changes for Reyataz [atazanavir] [Internet]. 2014 Jun 6 [cited 2014 Sep 4]. Available from: http://content.govdelivery.com/accounts/USFDA/bulletins/bcr4eb9

21. US Food and Drug Administration. New pediatric labeling information database – Reyataz [Internet]. 2014 Jun 2 [cited 2015 Feb 4]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206352s000,02156769358lbl.pdf

22. Centers for Disease Control and Prevention. Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years – United States, 2008. Mortb Mortal Wkly Rep. 2008;57(RR-10):1–12.

23. Centers for Disease Control and Prevention. Revised surveillance case definition for HIV infection – United States, 2014. Mortb Mortal Wkly Rep. 2014;63(RR-03):1–10.

24. DAIDS Regulatory Support Centre. Division of AIDS table for grading the severity of adult and pediatric adverse events version 1.0, December, 2004; Clarification August 2009 [Internet]. 2009 Aug [cited 2014 Aug 13]. Available from: http://nci.tech-res.com/Document/safetyandpharmacovigilance/Table__for_Grading_Severity_of_Adult_Pediatric_Adverse_Events.pdf

25. Atarax 10mg Film-coated Tablets [Hydroxyzine] – Summary of Product Characteristics [Internet]. 2013 Apr 4 [cited 2014 Jul 18]. Available from: http://www.medicines.org.uk/emc/medicine/20061/SFC

26. Cohen D, Saar N, Swartzon M, Klun-Ben-Bassat O, Justo D. First report of nevirapine-induced QT interval prolongation. Int J Antimicrob Agents. 2008;31(2):180–1.

27. Lopez JA, Harold JG, Rosenthal MC, Oseran DS, Schapira JN, Peter T. QT prolongation and torsades de pointes after administration of trimethoprim-sulfamethoxazole. Am J Cardiol. 1987;59(4):376–7.

28. Johnson M, Grinsztejn B, Rodriguez C, Coco I, Deless E, Lazzarin A, et al. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS. 2006;20(5):711–8.

29. Molina JM, Andrade-Villanueva J, Echevarria J, Chetchotisakd P, Corral J, David N, et al. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr. 2010;53(3):323–32.

30. Daar ES, Tierney C, Fischl MA, Sax PE, Mollan K, Budhathoki C, et al. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med. 2011;154(7):445–56.

31. Boulware DR, Callens S, Pahwa S. Pediatric HIV immune reconstitution inflammatory syndrome. Curr Opin HIV AIDS. 2008;3(4):461–7.

32. Palumbo P, Wu H, Chadwick E, Ruan P, Lutziraga K, Rodman J, et al. Virologic response to potent antiretroviral therapy and modeling of HIV dynamics in early pediatric infection. J Infect Dis. 2007;196(1):23–39.

33. Tobin NH, Aldrovandi GM. Immunology of pediatric HIV infection. Immunol Rev. 2013;254(1):143–69.

34. Turlova A, Webb RH, Lyall H. When to start, what to start and other treatment controversies in pediatric HIV infection. Paediatr Drugs. 2012;14(6):361–76.

35. Babiker A, Castro neo Green H, Compagnucci A, Fiscus S, Giagianto Q, Gibb DM, et al. First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus lower viral load in HIV-infected children: an open-label, randomised phase 2/3 trial. Lancet Infect Dis. 2011;11(4):273–83.

36. Violant A, Lindsey JC, Hughes MD, Mujuru HA, Barlow-Mosha L, Kamthunzi P, et al. Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children. N Engl J Med. 2012;366(15):2360–9.

37. Palumbo P, Lindsey JC, Hughes MD, Cotton MF, Bobat R, Meyers T, et al. Antiretroviral treatment for children with peripartum nevirapine exposure. N Engl J Med. 2010;363(16):1510–20.

38. Cotton M, Cassim H, Pavia-Ruz N, Garges HP, Perger T, Ford SL, et al. Pharmacokinetics and 48-week safety and antiviral activity of fosamprenavir/ritonavir-containing regimens in HIV-infected children aged 4 weeks to 2 years-48-week study data. Pediatr Infect Dis J. 2014;33(1):57–62.

39. Fortuny C, Duiculescu D, Cheng K, Garges HP, Cotton M, Tamartir DP, et al. Pharmacokinetics and 48-week safety and antiviral activity of fosamprenavir-containing regimens in HIV-infected 2- to 18-year-old children. Pediatr Infect Dis J. 2014;33(1):50–6.

40. Blanche S, Bologna R, Cahn P, Rugina S, Flynn P, Fortuny C, et al. Pharmacokinetics, safety and efficacy of darunavir/ritonavir in treatment-experienced children and adolescents. AIDS. 2009;23(15):2005–13.

41. Lin S, Seabrook JA, Matsui DM, King SM, Rieder MJ, Finkelstein Y. Palatability, adherence and prescribing patterns of antiretroviral drugs for children with human immunodeficiency virus infection in Canada. Pharma-coepidemiol Drug Saf. 2011;20(12):1246–52.